Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction.

Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, Piccirillo CA, Salomon BL, Bluestone JA.

Immunity. 2008 May;28(5):687-97. doi: 10.1016/j.immuni.2008.03.016. Epub 2008 May 8.

2.

Linked T cell receptor and cytokine signaling govern the development of the regulatory T cell repertoire.

Burchill MA, Yang J, Vang KB, Moon JJ, Chu HH, Lio CW, Vegoe AL, Hsieh CS, Jenkins MK, Farrar MA.

Immunity. 2008 Jan;28(1):112-21. doi: 10.1016/j.immuni.2007.11.022.

3.

A two-step process for thymic regulatory T cell development.

Lio CW, Hsieh CS.

Immunity. 2008 Jan;28(1):100-11. doi: 10.1016/j.immuni.2007.11.021.

4.

The biology of interleukin-2.

Malek TR.

Annu Rev Immunol. 2008;26:453-79. Review.

PMID:
18062768
5.

Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature.

Hill JA, Feuerer M, Tash K, Haxhinasto S, Perez J, Melamed R, Mathis D, Benoist C.

Immunity. 2007 Nov;27(5):786-800.

6.

STAT5 is essential for Akt/p70S6 kinase activity during IL-2-induced lymphocyte proliferation.

Lockyer HM, Tran E, Nelson BH.

J Immunol. 2007 Oct 15;179(8):5301-8.

7.

Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma.

Waldmann TA.

Oncogene. 2007 May 28;26(25):3699-703. Review.

PMID:
17530023
8.
9.

Function of the IL-2R for thymic and peripheral CD4+CD25+ Foxp3+ T regulatory cells.

Bayer AL, Yu A, Malek TR.

J Immunol. 2007 Apr 1;178(7):4062-71.

10.

Cutting Edge: IL-2 is essential for TGF-beta-mediated induction of Foxp3+ T regulatory cells.

Davidson TS, DiPaolo RJ, Andersson J, Shevach EM.

J Immunol. 2007 Apr 1;178(7):4022-6.

11.

Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity.

Yamanouchi J, Rainbow D, Serra P, Howlett S, Hunter K, Garner VE, Gonzalez-Munoz A, Clark J, Veijola R, Cubbon R, Chen SL, Rosa R, Cumiskey AM, Serreze DV, Gregory S, Rogers J, Lyons PA, Healy B, Smink LJ, Todd JA, Peterson LB, Wicker LS, Santamaria P.

Nat Genet. 2007 Mar;39(3):329-37. Epub 2007 Feb 4.

12.
13.

Regulatory T cell development in the absence of functional Foxp3.

Lin W, Haribhai D, Relland LM, Truong N, Carlson MR, Williams CB, Chatila TA.

Nat Immunol. 2007 Apr;8(4):359-68. Epub 2007 Feb 2.

PMID:
17273171
14.

Nonredundant roles for Stat5a/b in directly regulating Foxp3.

Yao Z, Kanno Y, Kerenyi M, Stephens G, Durant L, Watford WT, Laurence A, Robinson GW, Shevach EM, Moriggl R, Hennighausen L, Wu C, O'Shea JJ.

Blood. 2007 May 15;109(10):4368-75. Epub 2007 Jan 16.

15.

Foxp3-dependent programme of regulatory T-cell differentiation.

Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA, Rudensky AY.

Nature. 2007 Feb 15;445(7129):771-5. Epub 2007 Jan 14.

PMID:
17220874
16.

Novel animal models for Sjögren's syndrome: expression and transfer of salivary gland dysfunction from regulatory T cell-deficient mice.

Sharma R, Zheng L, Guo X, Fu SM, Ju ST, Jarjour WN.

J Autoimmun. 2006 Dec;27(4):289-96. Epub 2007 Jan 3.

17.

IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells.

Burchill MA, Yang J, Vogtenhuber C, Blazar BR, Farrar MA.

J Immunol. 2007 Jan 1;178(1):280-90.

18.
19.

Bone marrow versus thymic pathways of natural killer cell development.

Di Santo JP, Vosshenrich CA.

Immunol Rev. 2006 Dec;214:35-46. Review.

PMID:
17100874
Items per page

Supplemental Content

Write to the Help Desk